<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367105</url>
  </required_header>
  <id_info>
    <org_study_id>ENDA-034-12F</org_study_id>
    <secondary_id>CX000906</secondary_id>
    <nct_id>NCT02367105</nct_id>
  </id_info>
  <brief_title>Lifestyle Intervention and Testosterone Replacement in Obese Seniors</brief_title>
  <acronym>LITROS</acronym>
  <official_title>Testosterone Replacement to Augment Lifestyle Therapy in Obese Older Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael E. DeBakey VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biomedical Research Institute of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of obesity in Veterans is greater than in the general population, and even&#xD;
      more so among users of the VA Health Care System. In addition, the population of obese older&#xD;
      Veterans is rapidly increasing as more baby boomers become senior citizens. In older&#xD;
      Veterans, obesity exacerbates the age- related decline in physical function and causes&#xD;
      frailty which predisposes to admission to a VA chronic care facility. However, the optimal&#xD;
      clinical approach to obesity in older adults is controversial because of the concern that&#xD;
      weight loss therapy could be harmful by aggravating the age-related loss of muscle mass and&#xD;
      bone mass. In fact, the MOVE (Managing Overweight/Obese Veterans) program does not have any&#xD;
      guidelines for eligible Veterans if they are 70 or older. It is possible that the addition of&#xD;
      testosterone replacement to lifestyle therapy will preserve muscle mass and bone mass and&#xD;
      reverse frailty in obese older Veterans and thus prevent their loss of independence and&#xD;
      decrease demand for VA health care services.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is not only highly prevalent among Americans, but even more so among Veterans using&#xD;
      VA medical facilities. Failure to assist Veterans in managing weight and sedentary lifestyle&#xD;
      affects current treatment and increases future demand for VA health care services. Decreased&#xD;
      muscle mass with aging and the need to carry extra mass due to obesity make it particularly&#xD;
      difficult for obese older Veterans to function independently and results in frailty leading&#xD;
      to increased nursing home admissions and increased morbidity and mortality. Data from&#xD;
      preliminary studies showed that lifestyle therapy resulting in weight loss in this&#xD;
      understudied population improves physical function and ameliorates frailty. However, this&#xD;
      improvement in physical function is modest at best and most obese older adults remain&#xD;
      physically frail. More importantly, there are concerns that lifestyle therapy may exacerbate&#xD;
      underlying sarcopenia and osteopenia from weight loss- induced loss of lean body mass and&#xD;
      bone mineral density (BMD). As a result, most geriatricians are reluctant to recommend&#xD;
      lifestyle therapy that includes weight loss in obese frail elderly patients although the&#xD;
      combination of weight loss and exercise is recommended as part of standard care for obese&#xD;
      patients in general. Thus, it is not surprising that among Veterans, the MOVE (Managing&#xD;
      Overweight/Obese Veterans) program does not have any guidelines for eligible Veterans if they&#xD;
      are 70 or older. In addition to overeating and lack of exercise, age-related decline in&#xD;
      anabolic hormone (i.e. testosterone) may contribute to sarcopenia and osteopenia, which in&#xD;
      turn is exacerbated by obesity. Indeed, preliminary studies discovered that obese older men&#xD;
      had markedly low levels of serum testosterone at baseline which remained low throughout the&#xD;
      duration of lifestyle therapy. Because testosterone replacement therapy has been shown to&#xD;
      increase muscle mass and BMD, it is therefore likely that concomitant testosterone&#xD;
      replacement during lifestyle therapy in obese older adults would preserve lean body mass and&#xD;
      BMD, and reverse frailty. Accordingly, the optimal management to the problem of sarcopenic&#xD;
      obesity and frailty might require a comprehensive approach of a combination of lifestyle&#xD;
      intervention and the correction of anabolic hormone deficiency. Therefore, the primary goal&#xD;
      of this proposal is to conduct a randomized, comparative efficacy, double-blind,&#xD;
      placebo-controlled (for testosterone) trial of the effects of 1) lifestyle therapy (1%&#xD;
      diet-induced weight loss and exercise training) + testosterone replacement therapy versus 2)&#xD;
      lifestyle therapy without testosterone replacement (testosterone placebo) in obese (BMI e 30&#xD;
      kg/m2) older (age e 65 yrs) male Veterans. The investigators hypothesize that 1) lifestyle&#xD;
      therapy + testosterone replacement will cause a greater improvement in physical function than&#xD;
      lifestyle therapy without concomitant testosterone replacement; 2) lifestyle therapy +&#xD;
      testosterone replacement will cause a greater preservation of fat-free mass and thigh muscle&#xD;
      volume than lifestyle therapy without testosterone replacement, 3) lifestyle therapy +&#xD;
      testosterone replacement will cause a greater preservation in BMD and bone quality than&#xD;
      lifestyle therapy without testosterone replacement, and 4) lifestyle therapy + testosterone&#xD;
      replacement will cause a greater reduction in intramuscular proinflammatory cytokines than&#xD;
      lifestyle therapy without testosterone replacement. The overarching hypothesis across aims is&#xD;
      that a multifactorial intervention by means of lifestyle therapy plus testosterone&#xD;
      replacement will be the most effective approach for reversing sarcopenic obesity and frailty&#xD;
      in obese older male adults, as mediated by their additive effects in suppressing chronic&#xD;
      inflammation, and stimulating muscle and bone anabolism. Obesity in older adults, including&#xD;
      many aging Veterans, is a major public health problem. In fact, the public health success&#xD;
      that has occurred in recent years could be in danger if lifestyles of older adults are&#xD;
      neglected. The novel health outcomes and mechanistic-based data generated from this proposed&#xD;
      randomized clinical trial (RCT) will have important ramifications for the standard of care&#xD;
      for this rapidly increasing segment of the aging Veteran population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2015</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Physical Performance Test</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The primary functional outcome is the modified physical performance test, which includes seven standardized tasks (walking 50 ft, putting on and removing a coat, picking up a penny, standing up from a chair, lifting a book, climbing one flight of stairs, and performing a progressive Romberg tests) plus two additional tasks (climbing up and down four flights of stairs and performing a 360-degree turn). The score for each task ranges form 0 to 4; a perfect score is 36. Higher scores indicate better physical function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Endurance Capacity</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assessed by measuring peak oxygen consumption using indirect calorimetry during a treadmill exercise stress test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assessed by the Functional Status Questionnaire. Score range: 0 to 36 with higher scores indicating better functional status&#xD;
Provides information of the participants ability to perform activities of daily living.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Measured after an overnight fast using calibrated scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lean Body Mass</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assessed by using dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fat Mass</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assessed by using dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thigh Muscle Volume</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assessed by using magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thigh Fat Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Volume of fat in the thigh by measured by magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Hip Bone Mineral Density</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assessed by using dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lumbar Spine Bone Mineral Density</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>As measured by Dual energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Strength</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>assessed by total1-repetition maximum (the maximal weight lifted at one time; the totals are the sum of the maximal weights lifted in the biceps curl, bench press, 387 seated row, knee extension, knee flexion, and leg press exercises).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Static Balance</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>assessed by one leg limb stance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dynamic Balance</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assessed by using the obstacle course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gait Speed</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Determined by measuring the time needed to walk 25 ft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Composite Cognitive Z-score</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Test of overall cognitive performance formed by averaging the standardized scores for several domains of cognitive function (attention, memory, executive, language, global). Higher scores indicate better cognitive status.&#xD;
The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of the baseline scores (units on a scale). Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Mini-mental Exam</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Test of global cognition with components for orientation, registration, attention, language, praxis, and immediate and delayed memory. Score ranges from 0 to 100 with higher scores indicate better cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop Interference</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Word List Fluency</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Measure of verbal production, semantic memory, and language. Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ray Auditory Verbal Learning Test</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The Rey Auditory Verbal Learning Test (RAVLT) evaluates a wide diversity of functions: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Trail A</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Test of visuospatial scanning, speed of processing, mental flexibility, and executive function (with a greater focus on attention).&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Trail B</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Test of visuospatial scanning, speed of processing, mental flexibility, and executive function (with a focus on executive function)&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Symbol Digital Modalities Test</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assesses key neurocognitive functions that underlie many substitution tasks, including attention, visual scanning, and motor speed.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Trabecular Bone Score</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>The trabecular bone score is a measure of bone texture correlated with bone microarchitecture and a marker for the risk of osteoporosis.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better bone microarchitecture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-terminal Telopeptide</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>biochemical marker of bone turnover (bone resorption) as measured by immunoassay technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Propeptide of Type I Procollagen</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Biochemical marker of bone turnover (bone formation) as measured by radioimmunoassay technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Growth Factor-1</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Measured by immunoassay methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Trabecular Bone Score (Trabecular Bone Quality)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>assessed by trabecular bone score (TBS), a newly developed index for assessing trabecular bone quality and fracture risk. TBS is a bone texture parameter that quantifies cancellous bone microachitecture, which is key in determining bone strength and resistance to fracture, by computing raw data from dual energy x-ray absorptiometry of the lumbar spine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of 25-hydroxyvitamin D</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>assessed by using immunoassay methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parathyroid Hormone Level</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Measured by immunoassay methodology as marker of bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High-sensitivity C-reactive Protein (Inflammatory Marker)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>measured in the peripheral blood using immunoassay technique methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-6</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Measured from fasting serum using immunoassay technique as marker of inflammation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Total Testosterone Levels</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>as measured in the peripheral blood by liquid chromatography/mass spectrometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Estradiol</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>As measured by LC-MS/MS</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hematocrit</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>the ratio of the volume of red blood cells to the total volume of blood.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Prostate Specific Antigen</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>blood test to screen for prostate cancer</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Short Form Health Survey (SF-36) Quality of Life Physical Component</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Using Short Form-36 of Life Questionnaire Physical Component subscale. Minimum score is 0, Maximum score is 100. Higher scores indicate better outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in International Prostate Symptom Score</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Using the International Prostate Symptom Scoring (IPS); Minimum score is 0, Maximum score is 35. Higher scores mean worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Triglyceride Levels</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Blood samples obtained in the fasting state as part of measurements of lipid profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HDL-cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>Blood samples obtained in the fasting state as part of measurements of lipid profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Waist circumference as measured horizontally at the midpoint between the highest point of the iliac crest and the lowest portion of the 12th rib in the standing position.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Glucose</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Measured in the blood after overnight fast</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Mood</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Using Yesavage Depression Scale Lower scores indicate better mood (range 0 to 30).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in BRAIN MRI Including Functional Connectivity</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Measured by functional connectivity parameters of resting brain MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Skeletal Muscle Cytokines, Mitochondrial Function, and Growth Factors</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Assessed by using reverse transcription-polymerase chain reaction (RT-PCR) and western blotting and/or microarray expression of skeletal muscles obtained during muscle biopsies. May also consider metabolomics and/or proteonomic based assays of metabolites and proteins to comprehensively understand mechanisms and/or mediator for the effects.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Peripheral Quantitative Computed Tomography Measures</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>assessed by quantitative computed tomography including volumetric bone mineral density</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Obesity and Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosterone plus Lifestyle Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Lifestyle Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Daily testosterone gel applied once daily in the morning to intact skin</description>
    <arm_group_label>Testosterone plus Lifestyle Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lifestyle Therapy</intervention_name>
    <description>Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
    <arm_group_label>Placebo plus Lifestyle Therapy</arm_group_label>
    <arm_group_label>Testosterone plus Lifestyle Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo gel for testosterone</description>
    <arm_group_label>Placebo plus Lifestyle Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects will be&#xD;
&#xD;
          -  older (65-85 yr)&#xD;
&#xD;
          -  obese (BMI 30 kg/m2 or greater) Veteran men with low testosterone (less than 300&#xD;
             mg/dL) as defined by the Endocrine Society&#xD;
&#xD;
          -  mild to moderately frail&#xD;
&#xD;
          -  must have stable weight (~not less than or more than 2 kg) during the last 6 months&#xD;
&#xD;
          -  sedentary (regular exercise less than 1 h/week or less than 2x/week for the last 6&#xD;
             months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any major chronic diseases, or any condition that would interfere with exercise or&#xD;
             dietary restriction, in which exercise or dietary restriction are contraindicated, or&#xD;
             that would interfere with interpretation of results.&#xD;
&#xD;
          -  Examples include, but are not limited to:&#xD;
&#xD;
               -  cardiopulmonary disease (e.g. recent myocardial infarction (MI), unstable angina,&#xD;
                  stroke etc) or unstable disease (e.g. CHF)&#xD;
&#xD;
               -  severe orthopedic/musculoskeletal or neuromuscular impairments&#xD;
&#xD;
               -  visual or hearing impairments&#xD;
&#xD;
               -  cognitive impairment (Mini Mental State Exam Score less than 24)&#xD;
&#xD;
               -  current use of bone active drugs&#xD;
&#xD;
               -  uncontrolled diabetes (i.e. fasting blood glucose more than 140 mg/dl and/or&#xD;
                  HbA1c greater than 9.5%).&#xD;
&#xD;
          -  Any contraindications to testosterone supplementation&#xD;
&#xD;
               -  history of prostate or breast cancer&#xD;
&#xD;
               -  history of testicular disease&#xD;
&#xD;
               -  untreated sleep apnea&#xD;
&#xD;
               -  hematocrit more than 50%&#xD;
&#xD;
               -  prostate-related findings of palpable nodule on exam, a serum PSA of 4.0 ng/ml or&#xD;
                  greater&#xD;
&#xD;
               -  International Prostate Symptom Sore more than 19&#xD;
&#xD;
               -  history of venous thromboembolism&#xD;
&#xD;
          -  Osteoporosis or a BMD T-score of -2.5 in the lumbar spine or total hip as well as&#xD;
             those patients with a history of osteoporosis-related fracture (spine, hip, or wrist)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis T Villareal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michael E. DeBakey VA Medical Center, Houston, TX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center, Houston, TX</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <results_first_submitted>July 22, 2020</results_first_submitted>
  <results_first_submitted_qc>August 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2020</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Frailty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Publications from this research will be made available to the public through the National Library of Medicine PubMed Central website within one year after the date of publication (guidance is provided on the ORD website).&#xD;
MEDVAMC will not provide unrestricted, open public access to large scale health related datasets because of re-identification concerns and the obligation to protect Veterans' private information. However, controlled public access will be provided to the greatest extent possible under specific DUAs or other written agreements, and open access will be provided to the final datasets underlying peer-reviewed publications (aggregated data that can be released with privacy and confidentiality risks).</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02367105/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through advertisements and review of medical records at the Michael E DeBakey VA Medical Center.</recruitment_details>
      <pre_assignment_details>After obtaining written informed consent, potential participants underwent a comprehensive medical screening procedure, including an exercise stress test. If they were found eligible based on the inclusion/exclusion criteria, they were randomized into one of the two treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo + Lifestyle Therapy</title>
          <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
        </group>
        <group group_id="P2">
          <title>Testosterone + Lifestyle Therapy</title>
          <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo + Lifestyle Therapy</title>
          <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
        </group>
        <group group_id="B2">
          <title>Testosterone + Lifestyle Therapy</title>
          <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.2" spread="3.2"/>
                    <measurement group_id="B2" value="73.6" spread="3.7"/>
                    <measurement group_id="B3" value="73.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Ethnicity was reported by the participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Race was reported by the participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <description>The body-mass index is the weight in kilograms divided by the square of the height in meters</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.9" spread="4.9"/>
                    <measurement group_id="B2" value="37.1" spread="5.6"/>
                    <measurement group_id="B3" value="37.0" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total testosterone level</title>
          <description>Measured in the blood during early am in the fasting state.</description>
          <units>ng/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218" spread="43"/>
                    <measurement group_id="B2" value="210" spread="63"/>
                    <measurement group_id="B3" value="214" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physical Performance Test score</title>
          <description>The test includes walking 50 ft, putting on and removing a coat, picking up a penny, standing from a chair, lifting a book, climbing a flight of stairs, climbing up and down 4 flight of stairs, and performing a 360-degree turn. The score for each task ranges from 0 to 4; a perfect score is 36. Higher scores indicate better physical function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="3.1"/>
                    <measurement group_id="B2" value="28.5" spread="2.8"/>
                    <measurement group_id="B3" value="28.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Physical Performance Test</title>
        <description>The primary functional outcome is the modified physical performance test, which includes seven standardized tasks (walking 50 ft, putting on and removing a coat, picking up a penny, standing up from a chair, lifting a book, climbing one flight of stairs, and performing a progressive Romberg tests) plus two additional tasks (climbing up and down four flights of stairs and performing a 360-degree turn). The score for each task ranges form 0 to 4; a perfect score is 36. Higher scores indicate better physical function.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Physical Performance Test</title>
          <description>The primary functional outcome is the modified physical performance test, which includes seven standardized tasks (walking 50 ft, putting on and removing a coat, picking up a penny, standing up from a chair, lifting a book, climbing one flight of stairs, and performing a progressive Romberg tests) plus two additional tasks (climbing up and down four flights of stairs and performing a 360-degree turn). The score for each task ranges form 0 to 4; a perfect score is 36. Higher scores indicate better physical function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.3"/>
                    <measurement group_id="O2" value="4.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Endurance Capacity</title>
        <description>Assessed by measuring peak oxygen consumption using indirect calorimetry during a treadmill exercise stress test</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endurance Capacity</title>
          <description>Assessed by measuring peak oxygen consumption using indirect calorimetry during a treadmill exercise stress test</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.3"/>
                    <measurement group_id="O2" value="4.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status</title>
        <description>Assessed by the Functional Status Questionnaire. Score range: 0 to 36 with higher scores indicating better functional status&#xD;
Provides information of the participants ability to perform activities of daily living.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status</title>
          <description>Assessed by the Functional Status Questionnaire. Score range: 0 to 36 with higher scores indicating better functional status&#xD;
Provides information of the participants ability to perform activities of daily living.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.4"/>
                    <measurement group_id="O2" value="3.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.97</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <description>Measured after an overnight fast using calibrated scales</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Measured after an overnight fast using calibrated scales</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="0.6"/>
                    <measurement group_id="O2" value="-9.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lean Body Mass</title>
        <description>Assessed by using dual-energy x-ray absorptiometry</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lean Body Mass</title>
          <description>Assessed by using dual-energy x-ray absorptiometry</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="0.2"/>
                    <measurement group_id="O2" value="-1.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fat Mass</title>
        <description>Assessed by using dual-energy x-ray absorptiometry</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fat Mass</title>
          <description>Assessed by using dual-energy x-ray absorptiometry</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="0.4"/>
                    <measurement group_id="O2" value="-8.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thigh Muscle Volume</title>
        <description>Assessed by using magnetic resonance imaging</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thigh Muscle Volume</title>
          <description>Assessed by using magnetic resonance imaging</description>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68" spread="10"/>
                    <measurement group_id="O2" value="-25" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-42</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thigh Fat Volume</title>
        <description>Volume of fat in the thigh by measured by magnetic resonance imaging</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Thigh Fat Volume</title>
          <description>Volume of fat in the thigh by measured by magnetic resonance imaging</description>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-292" spread="31"/>
                    <measurement group_id="O2" value="-262" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.67</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-29</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Hip Bone Mineral Density</title>
        <description>Assessed by using dual-energy x-ray absorptiometry</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Hip Bone Mineral Density</title>
          <description>Assessed by using dual-energy x-ray absorptiometry</description>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.002"/>
                    <measurement group_id="O2" value="0.007" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline valued adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.019</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lumbar Spine Bone Mineral Density</title>
        <description>As measured by Dual energy x-ray absorptiometry</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lumbar Spine Bone Mineral Density</title>
          <description>As measured by Dual energy x-ray absorptiometry</description>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.004"/>
                    <measurement group_id="O2" value="0.007" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.003</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Muscle Strength</title>
        <description>assessed by total1-repetition maximum (the maximal weight lifted at one time; the totals are the sum of the maximal weights lifted in the biceps curl, bench press, 387 seated row, knee extension, knee flexion, and leg press exercises).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Muscle Strength</title>
          <description>assessed by total1-repetition maximum (the maximal weight lifted at one time; the totals are the sum of the maximal weights lifted in the biceps curl, bench press, 387 seated row, knee extension, knee flexion, and leg press exercises).</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="5"/>
                    <measurement group_id="O2" value="68" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Static Balance</title>
        <description>assessed by one leg limb stance</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Static Balance</title>
          <description>assessed by one leg limb stance</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="0.9"/>
                    <measurement group_id="O2" value="5.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dynamic Balance</title>
        <description>Assessed by using the obstacle course</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dynamic Balance</title>
          <description>Assessed by using the obstacle course</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="0.3"/>
                    <measurement group_id="O2" value="-3.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gait Speed</title>
        <description>Determined by measuring the time needed to walk 25 ft.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gait Speed</title>
          <description>Determined by measuring the time needed to walk 25 ft.</description>
          <units>m/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.3"/>
                    <measurement group_id="O2" value="8.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Baseline value adjusted</non_inferiority_desc>
            <p_value>0.96</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Composite Cognitive Z-score</title>
        <description>Test of overall cognitive performance formed by averaging the standardized scores for several domains of cognitive function (attention, memory, executive, language, global). Higher scores indicate better cognitive status.&#xD;
The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of the baseline scores (units on a scale). Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Composite Cognitive Z-score</title>
          <description>Test of overall cognitive performance formed by averaging the standardized scores for several domains of cognitive function (attention, memory, executive, language, global). Higher scores indicate better cognitive status.&#xD;
The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of the baseline scores (units on a scale). Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population</description>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".273" spread=".061"/>
                    <measurement group_id="O2" value=".557" spread=".065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-.284</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Modified Mini-mental Exam</title>
        <description>Test of global cognition with components for orientation, registration, attention, language, praxis, and immediate and delayed memory. Score ranges from 0 to 100 with higher scores indicate better cognition.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Modified Mini-mental Exam</title>
          <description>Test of global cognition with components for orientation, registration, attention, language, praxis, and immediate and delayed memory. Score ranges from 0 to 100 with higher scores indicate better cognition.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.3"/>
                    <measurement group_id="O2" value="2.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.16</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value and years of education as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroop Interference</title>
        <description>Assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Stroop Interference</title>
          <description>Assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.7"/>
                    <measurement group_id="O2" value="3.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values and years of education as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Word List Fluency</title>
        <description>Measure of verbal production, semantic memory, and language. Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Word List Fluency</title>
          <description>Measure of verbal production, semantic memory, and language. Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="0.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values and years of education as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ray Auditory Verbal Learning Test</title>
        <description>The Rey Auditory Verbal Learning Test (RAVLT) evaluates a wide diversity of functions: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ray Auditory Verbal Learning Test</title>
          <description>The Rey Auditory Verbal Learning Test (RAVLT) evaluates a wide diversity of functions: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.9"/>
                    <measurement group_id="O2" value="7.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.03</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value and years if education as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Trail A</title>
        <description>Test of visuospatial scanning, speed of processing, mental flexibility, and executive function (with a greater focus on attention).&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Trail A</title>
          <description>Test of visuospatial scanning, speed of processing, mental flexibility, and executive function (with a greater focus on attention).&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="1.4"/>
                    <measurement group_id="O2" value="-13.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.03</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values and years of education as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Trail B</title>
        <description>Test of visuospatial scanning, speed of processing, mental flexibility, and executive function (with a focus on executive function)&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Trail B</title>
          <description>Test of visuospatial scanning, speed of processing, mental flexibility, and executive function (with a focus on executive function)&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="2.9"/>
                    <measurement group_id="O2" value="-19.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.18</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values and years of education as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Symbol Digital Modalities Test</title>
        <description>Assesses key neurocognitive functions that underlie many substitution tasks, including attention, visual scanning, and motor speed.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Symbol Digital Modalities Test</title>
          <description>Assesses key neurocognitive functions that underlie many substitution tasks, including attention, visual scanning, and motor speed.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.5"/>
                    <measurement group_id="O2" value="2.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values and years of education as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Trabecular Bone Score</title>
        <description>The trabecular bone score is a measure of bone texture correlated with bone microarchitecture and a marker for the risk of osteoporosis.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better bone microarchitecture.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Trabecular Bone Score</title>
          <description>The trabecular bone score is a measure of bone texture correlated with bone microarchitecture and a marker for the risk of osteoporosis.&#xD;
Minimum score is 0, there is no maximum value. Higher scores indicate better bone microarchitecture.</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread=".01"/>
                    <measurement group_id="O2" value=".11" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.65</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.01</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-terminal Telopeptide</title>
        <description>biochemical marker of bone turnover (bone resorption) as measured by immunoassay technique</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-terminal Telopeptide</title>
          <description>biochemical marker of bone turnover (bone resorption) as measured by immunoassay technique</description>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.530" spread=".012"/>
                    <measurement group_id="O2" value="0.002" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.553</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-terminal Propeptide of Type I Procollagen</title>
        <description>Biochemical marker of bone turnover (bone formation) as measured by radioimmunoassay technique</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>N-terminal Propeptide of Type I Procollagen</title>
          <description>Biochemical marker of bone turnover (bone formation) as measured by radioimmunoassay technique</description>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="1.4"/>
                    <measurement group_id="O2" value="1.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Growth Factor-1</title>
        <description>Measured by immunoassay methodology</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Growth Factor-1</title>
          <description>Measured by immunoassay methodology</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="2.8"/>
                    <measurement group_id="O2" value="16.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.35</p_value>
            <p_value_desc>Baseline value adjusted</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Trabecular Bone Score (Trabecular Bone Quality)</title>
        <description>assessed by trabecular bone score (TBS), a newly developed index for assessing trabecular bone quality and fracture risk. TBS is a bone texture parameter that quantifies cancellous bone microachitecture, which is key in determining bone strength and resistance to fracture, by computing raw data from dual energy x-ray absorptiometry of the lumbar spine</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Trabecular Bone Score (Trabecular Bone Quality)</title>
          <description>assessed by trabecular bone score (TBS), a newly developed index for assessing trabecular bone quality and fracture risk. TBS is a bone texture parameter that quantifies cancellous bone microachitecture, which is key in determining bone strength and resistance to fracture, by computing raw data from dual energy x-ray absorptiometry of the lumbar spine</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread=".01"/>
                    <measurement group_id="O2" value="0.12" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of 25-hydroxyvitamin D</title>
        <description>assessed by using immunoassay methodology</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of 25-hydroxyvitamin D</title>
          <description>assessed by using immunoassay methodology</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="1.1"/>
                    <measurement group_id="O2" value="8.3" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <p_value_desc>Baseline value adjusted</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Parathyroid Hormone Level</title>
        <description>Measured by immunoassay methodology as marker of bone metabolism</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Parathyroid Hormone Level</title>
          <description>Measured by immunoassay methodology as marker of bone metabolism</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="2.0"/>
                    <measurement group_id="O2" value="9.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <p_value_desc>Baseline value adjusted</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High-sensitivity C-reactive Protein (Inflammatory Marker)</title>
        <description>measured in the peripheral blood using immunoassay technique methodology</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-sensitivity C-reactive Protein (Inflammatory Marker)</title>
          <description>measured in the peripheral blood using immunoassay technique methodology</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".19" spread=".05"/>
                    <measurement group_id="O2" value=".18" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.01</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin-6</title>
        <description>Measured from fasting serum using immunoassay technique as marker of inflammation</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin-6</title>
          <description>Measured from fasting serum using immunoassay technique as marker of inflammation</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.2"/>
                    <measurement group_id="O2" value="-1.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Total Testosterone Levels</title>
        <description>as measured in the peripheral blood by liquid chromatography/mass spectrometry</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Testosterone Levels</title>
          <description>as measured in the peripheral blood by liquid chromatography/mass spectrometry</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="21"/>
                    <measurement group_id="O2" value="306" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-252</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Estradiol</title>
        <description>As measured by LC-MS/MS</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estradiol</title>
          <description>As measured by LC-MS/MS</description>
          <units>pg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="2.7"/>
                    <measurement group_id="O2" value="22.1" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-24.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hematocrit</title>
        <description>the ratio of the volume of red blood cells to the total volume of blood.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hematocrit</title>
          <description>the ratio of the volume of red blood cells to the total volume of blood.</description>
          <units>percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.3"/>
                    <measurement group_id="O2" value="2.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Prostate Specific Antigen</title>
        <description>blood test to screen for prostate cancer</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Prostate Specific Antigen</title>
          <description>blood test to screen for prostate cancer</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.1"/>
                    <measurement group_id="O2" value="0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Short Form Health Survey (SF-36) Quality of Life Physical Component</title>
        <description>Using Short Form-36 of Life Questionnaire Physical Component subscale. Minimum score is 0, Maximum score is 100. Higher scores indicate better outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form Health Survey (SF-36) Quality of Life Physical Component</title>
          <description>Using Short Form-36 of Life Questionnaire Physical Component subscale. Minimum score is 0, Maximum score is 100. Higher scores indicate better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.8"/>
                    <measurement group_id="O2" value="7.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <p_value_desc>Baseline values as covariates</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in International Prostate Symptom Score</title>
        <description>Using the International Prostate Symptom Scoring (IPS); Minimum score is 0, Maximum score is 35. Higher scores mean worse outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in International Prostate Symptom Score</title>
          <description>Using the International Prostate Symptom Scoring (IPS); Minimum score is 0, Maximum score is 35. Higher scores mean worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.5"/>
                    <measurement group_id="O2" value="-0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Triglyceride Levels</title>
        <description>Blood samples obtained in the fasting state as part of measurements of lipid profile</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglyceride Levels</title>
          <description>Blood samples obtained in the fasting state as part of measurements of lipid profile</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39" spread="5.4"/>
                    <measurement group_id="O2" value="-31" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline value adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in HDL-cholesterol</title>
        <description>Blood samples obtained in the fasting state as part of measurements of lipid profile</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL-cholesterol</title>
          <description>Blood samples obtained in the fasting state as part of measurements of lipid profile</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.0"/>
                    <measurement group_id="O2" value="0.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Waist Circumference</title>
        <description>Waist circumference as measured horizontally at the midpoint between the highest point of the iliac crest and the lowest portion of the 12th rib in the standing position.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <description>Waist circumference as measured horizontally at the midpoint between the highest point of the iliac crest and the lowest portion of the 12th rib in the standing position.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="0.5"/>
                    <measurement group_id="O2" value="-8.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values as covariates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Glucose</title>
        <description>Measured in the blood after overnight fast</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Plus Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose</title>
          <description>Measured in the blood after overnight fast</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5" spread="3.7"/>
                    <measurement group_id="O2" value="-17.1" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Mood</title>
        <description>Using Yesavage Depression Scale Lower scores indicate better mood (range 0 to 30).</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Lifestyle Therapy</title>
            <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
          </group>
          <group group_id="O2">
            <title>Testosterone + Lifestyle Therapy</title>
            <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mood</title>
          <description>Using Yesavage Depression Scale Lower scores indicate better mood (range 0 to 30).</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="0.38"/>
                    <measurement group_id="O2" value="-1.39" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Baseline values adjusted</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.31</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in BRAIN MRI Including Functional Connectivity</title>
        <description>Measured by functional connectivity parameters of resting brain MRI</description>
        <time_frame>Baseline and 6 months</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Skeletal Muscle Cytokines, Mitochondrial Function, and Growth Factors</title>
        <description>Assessed by using reverse transcription-polymerase chain reaction (RT-PCR) and western blotting and/or microarray expression of skeletal muscles obtained during muscle biopsies. May also consider metabolomics and/or proteonomic based assays of metabolites and proteins to comprehensively understand mechanisms and/or mediator for the effects.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Peripheral Quantitative Computed Tomography Measures</title>
        <description>assessed by quantitative computed tomography including volumetric bone mineral density</description>
        <time_frame>Baseline and 6 months</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo + Lifestyle Therapy</title>
          <description>Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week&#xD;
Placebo: Placebo gel for testosterone</description>
        </group>
        <group group_id="E2">
          <title>Testosterone + Lifestyle Therapy</title>
          <description>Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training&#xD;
Testosterone: Daily testosterone gel applied once daily in the morning to intact skin&#xD;
Lifestyle Therapy: Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperosmolar hyperglycemic state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia, asymptomatic and symptomatic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Elevated PSA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/orthostasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dennis T Villareal, MD</name_or_title>
      <organization>Michael E DeBakey VA Medical Center</organization>
      <phone>713-794-7156</phone>
      <email>dennis.villareal@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

